Ocumension Therapeutics (HK:1477) has released an update.
Ocumension Therapeutics has completed patient enrollment for its second phase III clinical trial of OT-301 in China, a promising treatment for lowering intraocular pressure in glaucoma and ocular hypertension patients. This development is part of a collaborative effort with Nicox S.A., advancing a novel drug candidate that combines nitric oxide with a prostaglandin analog. Investors should monitor Ocumension’s progress as this trial could significantly impact the company’s market position.
For further insights into HK:1477 stock, check out TipRanks’ Stock Analysis page.
